Transcription of Biosimilars in the EU
{{id}} {{{paragraph}}}
Example: bachelor of science
Biosimilars in the EU
Information guide for healthcare professionalsBiosimilars in the EUPrepared jointly by the European Medicines Agency and the European CommissionTable of contentsForeword 2 Summary 3 Biological medicines: overview 5 Key features of biological medicines 5 Biosimilar medicines: definition and features 8 Why Biosimilars are not considered generic medicines 10 Development and approval of Biosimilars in the EU 12A robust regulatory framework for Biosimilars 12 Process for approval of Biosimilars in the EU 12 Data requirements for approval: a scientifically tailored package 12 Immunogenicity 20 Extrapolation 22 Safety of Biosimilars 24 General considerations on safety for Biosimilars 24 Safety monitoring for all biological medicines, including Biosimilars 24 Traceability: importance of identifying biological medicines by tradename and batch number 25 How healthcare professionals can help improve pharmacovigilance for biological medicines: 26 Data included in the prescribing information and EMA assessment report
Commission and scientific experts from EU Member States. Information needs and feedback from EU healthcare professionals’ organisations have been sought throughout the preparation of this document. 2 . Summary Since the EU approved the first biosimilar medicine (‘biosimilar’) in 2006, the EU has pioneered
Loading..
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: